Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-Matched Unrelated Donors and Utilizing Two Graft-Versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders.

Next Previous
X
Search
Trial Profile

Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-Matched Unrelated Donors and Utilizing Two Graft-Versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders.

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab; Ciclosporin; Ciclosporin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Filgrastim; Fludarabine; Methotrexate; Prednisone; Rituximab; Sirolimus; Tacrolimus; Tacrolimus; Vincristine
  • Indications Acute myeloid leukaemia; B-cell prolymphocytic leukaemia; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Essential thrombocythaemia; Follicular lymphoma; Graft-versus-host disease; Haematological malignancies; Hodgkin's disease; Leukaemia; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Polycythaemia vera; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell prolymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 05 Mar 2019 Biomarkers information updated
    • 30 Jun 2010 Planned end date (1 Jun 2016) added as reported by ClinicalTrials.gov.
    • 01 May 2009 Planned number of patients changed from 20 to 85 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top